



**Emerging  
immunotherapies  
in cancer**

**Thursday 26th September, 2019**

Casa de Convalescència, Barcelona

For more information and registrations, please visit  
[www.fls-science.com/cancer](http://www.fls-science.com/cancer)



**FIGHT AIDS  
FOUNDATION**



**FLS SCIENCE**

08.30	Registration	
09.00	Welcome	<b>Leticia De Mattos</b> , IrsiCaixa Institute of Research, Barcelona.

## MORNING SESSION

TABLE I: CANCER AND THE IMMUNE SYSTEM: WHERE ARE WE HEADING TO		<b>CHAIR: Luis Paz-Ares</b> , Hospital Universitario 12 de Octubre, Madrid.
09.15	Cancer and the immune system: basic concepts and targets for therapy intervention	<b>Jorge Carrillo</b> , IrsiCaixa Institute of Research, Barcelona.
09.35	Predictive molecular factors of response beyond pd-1 expression	<b>Rafael Rosell</b> , Hospital Universitari Dexeus, Barcelona.
09.55	Overall discussion	
TABLE II: ACTIVATING VIRAL DEFENSE SIGNALING IN CANCER		<b>CHAIR: Antoni Ribas</b> , University of California Los Angeles, USA.
10.10	Innate immune agonists to improve the immunobiology of the tumor microenvironment	<b>Thomas Gajewski</b> , Chicago University, USA.
10.30	Intratumoral BO 112: viral mimicry in cancer therapy	<b>Iván Márquez</b> , Hospital Gregorio Marañón, Madrid.
10.50	Overall discussion	
11.05	Coffeebreak	
TABLE III: IMMUNO ONCOLOGY THERAPEUTIC STRATEGY		<b>CHAIR: María González-Cao</b> , Hospital Universitari Dexeus, Barcelona.
11.35	Neoadjuvant immunotherapy in lung cancer	<b>Mariano Provencio</b> , Grupo Español de Cáncer de Pulmón, Madrid.
11.55	Novel approaches beyond PD-1 inhibitors	<b>Luis Paz-Ares</b> , Hospital Universitario 12 de Octubre, Madrid.
12.15	Future Directions for CAR-T Therapy	<b>Manel Juan Otero</b> , Hospital Clínic de Barcelona.
12.35	Overall discussion	

TABLE IV: PERSONALIZED NEOANTIGEN VACCINE		<b>CHAIR: Manel Juan Otero</b> , Hospital Clínic de Barcelona.
12.50	Neoantigen identification as targets for cancer vaccines	<b>Leticia De Mattos</b> , IrsiCaixa Institute of Research, Barcelona.
13.10	eVLPs in cancer: from HIV vaccine to cancer therapy	<b>Julià Blanco</b> , IrsiCaixa Institute of Research, Barcelona.
13.30	Overall discussion	
13.50	Lunch break	

## AFTERNOON SESSION

TABLE V: NEW INSIGHTS: VIRUS AND CANCER		<b>CHAIR: Bonaventura Clotet</b> , IrsiCaixa Institute of Research, Barcelona.
14.50	Cancer virotherapy	<b>Ramon Alemany</b> , IDIBell, Barcelona.
15.10	Results of phase II study of durvalumab in cancer patients with HIV-1 infection (DURVAST trial)	<b>Maria González-Cao</b> , Hospital Universitari Dexeus, Barcelona.
15.30	Reinvigorating exhausted T cell responses in chronic virus infections	<b>Andreas Meyerhans</b> , Pompeu Fabra University, Barcelona.
15.50	Overall discussion	
TABLE VI: MICROBIOME AND BACTERIOTHERAPY IN CANCER		<b>CHAIR: Rafael Rosell</b> , Hospital Universitari Dexeus, Barcelona.
16.10	Microbiome in cancer	<b>Thomas Gajewski</b> , Chicago University, USA.
16.30	Overall discussion	
16.45	Closing lecture: Overcoming resistance to PD-1 blockade therapy	<b>Antoni Ribas</b> , University of California Los Angeles, USA.
Closure of the event		

With the scientific endorsement of



Sponsored by

